<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39359765</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>04</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2049-0801</ISSN><JournalIssue CitedMedium="Print"><Volume>86</Volume><Issue>10</Issue><PubDate><Year>2024</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Annals of medicine and surgery (2012)</Title><ISOAbbreviation>Ann Med Surg (Lond)</ISOAbbreviation></Journal><ArticleTitle>Impacts of COVID-19 on hemostasis: coagulation abnormalities and management perspectives.</ArticleTitle><Pagination><StartPage>5844</StartPage><EndPage>5850</EndPage><MedlinePgn>5844-5850</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/MS9.0000000000002237</ELocationID><Abstract><AbstractText>The COVID-19 pandemic caused by SARS-CoV-2 has transcended its initial characterization as a respiratory illness, revealing substantial implications for hemostasis and coagulation pathways. COVID-19-associated coagulopathies have emerged as critical determinants of disease severity and prognosis, presenting a multifaceted challenge in clinical management. This paper aims to elucidate the intricate interplay between COVID-19 and hemostasis, delving into the underlying mechanisms of coagulation abnormalities, exploring the spectrum of thrombotic complications, and discussing evolving management strategies. Therapeutic interventions and anticoagulation strategies tailored for managing COVID-19-related coagulopathies form a significant focus, encompassing prophylactic and therapeutic approaches, heparin-based therapies, and individualized treatment paradigms. This paper underscores the imperative for ongoing research endeavors to refine diagnostic modalities, identify novel therapeutic targets, and ascertain long-term sequelae of COVID-19-induced coagulation abnormalities. Ultimately, a comprehensive understanding of the intricate relationship between COVID-19 and hemostasis is pivotal in devising effective management strategies to mitigate thrombotic risks, improve clinical outcomes, and pave the way for tailored interventions in affected individuals.</AbstractText><CopyrightInformation>Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Obeagu</LastName><ForeName>Emmanuel Ifeanyi</ForeName><Initials>EI</Initials><AffiliationInfo><Affiliation>Department of Medical Laboratory Science.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tukur</LastName><ForeName>Muhammad</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Science Education, Faculty of Education, Kampala International University, Kampala, Uganda.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Akaba</LastName><ForeName>Kingsley</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Haematology, University of Calabar, Calabar, Cross-River State, Nigeria.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>07</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Ann Med Surg (Lond)</MedlineTA><NlmUniqueID>101616869</NlmUniqueID><ISSNLinking>2049-0801</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">anticoagulation</Keyword><Keyword MajorTopicYN="N">coagulopathy</Keyword><Keyword MajorTopicYN="N">hemostasis</Keyword><Keyword MajorTopicYN="N">thrombosis</Keyword></KeywordList><CoiStatement>The author declares no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>1</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>5</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>3</Day><Hour>10</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>3</Day><Hour>10</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>3</Day><Hour>4</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>7</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39359765</ArticleId><ArticleId IdType="pmc">PMC11444586</ArticleId><ArticleId IdType="doi">10.1097/MS9.0000000000002237</ArticleId><ArticleId IdType="pii">AMSU-D-24-00048</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ogar CO, Okoroiwu HU, Obeagu EI, et al. . Assessment of blood supply and usage pre-and during COVID-19 pandemic: a lesson from non-voluntary donation. Transfus Clin Biol 2021;28:68–72.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7836417</ArticleId><ArticleId IdType="pubmed">33080420</ArticleId></ArticleIdList></Reference><Reference><Citation>Kolodziej LM, van Lelyveld SF, Haverkort ME, et al. . High severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) household transmission rates detected by dense saliva sampling. Clin Infect Dis 2022;75:e10–e19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9047155</ArticleId><ArticleId IdType="pubmed">35385575</ArticleId></ArticleIdList></Reference><Reference><Citation>Obeagu EI. COVID-19: factors associated with implementation and practice of Covid-19 prevention. Int J Adv Multidiscip Res 2022;9:37–42.</Citation></Reference><Reference><Citation>Zheng Y, Li Y, Li M, et al. . COVID‐19 cooling: Nanostrategies targeting cytokine storm for controlling severe and critical symptoms. Med Res Rev 2024;44:738–811.</Citation><ArticleIdList><ArticleId IdType="pubmed">37990647</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas TS, Srinivasa S. Emerging contributions of endocrine pathophysiology in virus-related infectious disease: focus on the RAAS in COVID-19 and HIV. Renin Angiotensin Syst Cancer Lung Liver Infect Dis 2023;15:53–77.</Citation></Reference><Reference><Citation>Corre J, Sabbah M, Schjesvold F, et al. . Recent advancements in hematology: knowledge, methods and dissemination, part 2. Hemato 2021;2:79–88.</Citation></Reference><Reference><Citation>Lopes-Pacheco M, Silva PL, Cruz FF, et al. . Pathogenesis of multiple organ injury in COVID-19 and potential therapeutic strategies. Front Physiol 2021;12:593223.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7876335</ArticleId><ArticleId IdType="pubmed">33584343</ArticleId></ArticleIdList></Reference><Reference><Citation>van Eijk LE, Binkhorst M, Bourgonje AR, et al. . COVID‐19: immunopathology, pathophysiological mechanisms, and treatment options. J Pathol 2021;254:307–331.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8013908</ArticleId><ArticleId IdType="pubmed">33586189</ArticleId></ArticleIdList></Reference><Reference><Citation>Narayanan SA, Jamison DA, Jr, Guarnieri JW, et al. . A comprehensive SARS-CoV-2 and COVID-19 review, Part 2: host extracellular to systemic effects of SARS-CoV-2 infection. Eur J Hum Genet 2024;32:10–20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10772081</ArticleId><ArticleId IdType="pubmed">37938797</ArticleId></ArticleIdList></Reference><Reference><Citation>Quinaglia T, Shabani M, Breder I, et al. . Coronavirus disease-19: the multi-level, multi-faceted vasculopathy. Atherosclerosis 2021;322:39–50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7883684</ArticleId><ArticleId IdType="pubmed">33706082</ArticleId></ArticleIdList></Reference><Reference><Citation>Samaddar A, Grover M, Nag VL. Pathophysiology and potential therapeutic candidates for COVID-19: a poorly understood arena. Front Pharmacol 2020;1504.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7527880</ArticleId><ArticleId IdType="pubmed">33041830</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamel MH, Yin W, Zavaro C, et al. . Hyperthrombotic milieu in COVID-19 patients. Cells 2020;9:2392.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7694011</ArticleId><ArticleId IdType="pubmed">33142844</ArticleId></ArticleIdList></Reference><Reference><Citation>Magro G. COVID-19: Review on latest available drugs and therapies against SARS-CoV-2. Coagulation and inflammation cross-talking. Virus Res 2020;286:198070.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7305708</ArticleId><ArticleId IdType="pubmed">32569708</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker RC. COVID-19 update: Covid-19-associated coagulopathy. J Thromb Thrombolysis 2020;50:54–67.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7225095</ArticleId><ArticleId IdType="pubmed">32415579</ArticleId></ArticleIdList></Reference><Reference><Citation>Veluswamy P, Wacker M, Stavridis D, et al. . The SARS-CoV-2/receptor axis in heart and blood vessels: a crisp update on COVID-19 disease with cardiovascular complications. Viruses 2021;13:1346.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8310117</ArticleId><ArticleId IdType="pubmed">34372552</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu SW, Ilyas I, Weng JP. Endothelial dysfunction in COVID-19: an overview of the evidence, biomarkers, mechanisms, and potential therapies. Acta Pharmacol Sin 2023;44:695–709.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9574180</ArticleId><ArticleId IdType="pubmed">36253560</ArticleId></ArticleIdList></Reference><Reference><Citation>Hulscher N, Procter BC, Wynn C, et al. . Clinical approach to post-acute sequelae after COVID-19 infection and vaccination. Cureus 2023;15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10663976</ArticleId><ArticleId IdType="pubmed">38024037</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabaan AA, Al-Ahmed SH, Muhammad J, et al. . Role of inflammatory cytokines in COVID-19 patients: a review on molecular mechanisms, immune functions, immunopathology and immunomodulatory drugs to counter cytokine storm. Vaccines 2021;9:436.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8145892</ArticleId><ArticleId IdType="pubmed">33946736</ArticleId></ArticleIdList></Reference><Reference><Citation>Pasrija R, Naime M. The deregulated immune reaction and cytokines release storm (CRS) in COVID-19 disease. Int Immunopharmacol 2021;90:107225.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7691139</ArticleId><ArticleId IdType="pubmed">33302033</ArticleId></ArticleIdList></Reference><Reference><Citation>Darif D, Hammi I, Kihel A, et al. . The pro-inflammatory cytokines in COVID-19 pathogenesis: What goes wrong? Microb Pathog 2021;153:104799.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7889464</ArticleId><ArticleId IdType="pubmed">33609650</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang L, Xie X, Tu Z, et al. . The signal pathways and treatment of cytokine storm in COVID-19. Signal Transduct Target Ther 2021;6:255.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8261820</ArticleId><ArticleId IdType="pubmed">34234112</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowaiye AB, Okpalefe OA, Onuh Adejoke O, et al. . Attenuating the effects of novel COVID-19 (SARS-CoV-2) infection-induced cytokine storm and the implications. J Inflamm Res 2021;16:1487–1510.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8057798</ArticleId><ArticleId IdType="pubmed">33889008</ArticleId></ArticleIdList></Reference><Reference><Citation>Bahraini M, Dorgalaleh A. The impact of SARS-CoV-2 infection on blood coagulation and fibrinolytic pathways: a review of prothrombotic changes caused by COVID-19. InSeminars in Thrombosis and Hemostasis 2021;48:019–030.</Citation><ArticleIdList><ArticleId IdType="pubmed">34695858</ArticleId></ArticleIdList></Reference><Reference><Citation>Allegra A, Innao V, Allegra AG, et al. . Coagulopathy and thromboembolic events in patients with SARS-CoV-2 infection: pathogenesis and management strategies. Ann Hematol 2020;99:1953–1965.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7363407</ArticleId><ArticleId IdType="pubmed">32671455</ArticleId></ArticleIdList></Reference><Reference><Citation>Colling ME, Kanthi Y. COVID–19–associated coagulopathy: an exploration of mechanisms. Vasc Med 2020;25:471–478.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7306998</ArticleId><ArticleId IdType="pubmed">32558620</ArticleId></ArticleIdList></Reference><Reference><Citation>Sayyadi M, Hassani S, Shams M, et al. . Status of major hemostatic components in the setting of COVID-19: The effect on the endothelium, platelets, coagulation factors, fibrinolytic system, and complement. Ann Hematol 2023;102:1307–1322.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10115391</ArticleId><ArticleId IdType="pubmed">37074380</ArticleId></ArticleIdList></Reference><Reference><Citation>Suh YJ, Hong H, Ohana M, et al. . Pulmonary embolism and deep vein thrombosis in COVID-19: a systematic review and meta-analysis. Radiology 2021;298:E70–E80.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7745997</ArticleId><ArticleId IdType="pubmed">33320063</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Minno A, Ambrosino P, Calcaterra I, et al. . COVID-19 and venous thromboembolism: a meta-analysis of literature studies. InSeminars in thrombosis and hemostasis 2020;46:763–771.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7645842</ArticleId><ArticleId IdType="pubmed">32882719</ArticleId></ArticleIdList></Reference><Reference><Citation>Edizioni F. The pathogenesis of COVID-19: Hypercoagulation and D-dimer in thrombotic complications. J Health Soc Sci 2023;8:45–58.</Citation></Reference><Reference><Citation>Conway EM, Mackman N, Warren RQ, et al. . Understanding COVID-19-associated coagulopathy. Nat Rev Immunol 2022;22:639–649.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9362465</ArticleId><ArticleId IdType="pubmed">35931818</ArticleId></ArticleIdList></Reference><Reference><Citation>Obeagu EI, Nwosu DC, Obeagu GU. Interleukin-6 (IL-6): A Major target for quick recovery of COVID-19 patients. Int J Curr Res Biol Med 2022;7:1–19.</Citation></Reference><Reference><Citation>Ifeanyi OE, Mercy OH, Prayer NN, et al. . Cytokines, coagulation profile and haematological changes in covid 19 patients as indicators of their health staus: a review. Eur J Biomed 2020;7:724–729.</Citation></Reference><Reference><Citation>Obeagu EI, Scott GY, Amekpor F, et al. . Covid-19 infection and diabetes: a current issue. Int J Innov Appl Res 2023;11:25–30.</Citation></Reference><Reference><Citation>Hassan AO, Obeagu EI, Ajayi DT, et al. . COVID 19 Omicron: the origin, presentation, diagnosis. prevention and control. Asian J Res Infect Dis 2022;11:25–33.</Citation></Reference><Reference><Citation>Ifeanyi OE. Emerging clinical &amp; medical challenges and appropriate solutions during COVID-19 pandemic times. Med Clin Rev 2020;6:108.</Citation></Reference><Reference><Citation>De la Rica R, Borges M, Gonzalez-Freire M. COVID-19: in the eye of the cytokine storm. Front Immunol 2020;11:558898.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7541915</ArticleId><ArticleId IdType="pubmed">33072097</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen AT, Wang CY, Zhu WL, et al. . Coagulation disorders and thrombosis in COVID-19 patients and a possible mechanism involving endothelial cells: a review. Aging Dis 2022;13:144.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8782553</ArticleId><ArticleId IdType="pubmed">35111367</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao R, Su Z, Komissarov AA, et al. . Associations of D-dimer on admission and clinical features of COVID-19 patients: a systematic review, meta-analysis, and meta-regression. Front Immunol 2021;12:691249.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8138429</ArticleId><ArticleId IdType="pubmed">34025688</ArticleId></ArticleIdList></Reference><Reference><Citation>Lampsas S, Tsaplaris P, Pantelidis P, et al. . The role of endothelial related circulating biomarkers in COVID-19. A systematic review and meta-analysis. Curr Med Chem 2022;29:3790–3805.</Citation><ArticleIdList><ArticleId IdType="pubmed">34702152</ArticleId></ArticleIdList></Reference><Reference><Citation>Volteas P, Drakos P, Alkadaa LN, et al. . Low-molecular-weight heparin compared with unfractionated heparin in critically ill COVID-19 patients. J Vasc Surg Venous Lymph Disord 2022;10:1128–1136.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9212478</ArticleId><ArticleId IdType="pubmed">35716998</ArticleId></ArticleIdList></Reference><Reference><Citation>Reis S, Popp M, Schmid B, et al. . Safety and efficacy of intermediate-and therapeutic-dose anticoagulation for hospitalised patients with COVID-19: a systematic review and meta-analysis. J Clin Med 2021;11:57.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8745419</ArticleId><ArticleId IdType="pubmed">35011804</ArticleId></ArticleIdList></Reference><Reference><Citation>Jyotsna F, Mahfooz K, Sohail H, et al. . Deciphering the dilemma: anticoagulation for heart failure with preserved ejection fraction (HFpEF). Cureus 2023;15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10492587</ArticleId><ArticleId IdType="pubmed">37692595</ArticleId></ArticleIdList></Reference><Reference><Citation>Lucà F, Oliva F, Abrignani MG, et al. . Management of patients treated with direct oral anticoagulants in clinical practice and challenging scenarios. J Clin Med 2023;12:5955.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10531873</ArticleId><ArticleId IdType="pubmed">37762897</ArticleId></ArticleIdList></Reference><Reference><Citation>Quill TE, Brody H. Physician recommendations and patient autonomy: finding a balance between physician power and patient choice. Ann Intern Med 1996;125:763–769.</Citation><ArticleIdList><ArticleId IdType="pubmed">8929011</ArticleId></ArticleIdList></Reference><Reference><Citation>Forman DE, Rich MW, Alexander KP, et al. . Cardiac care for older adults: time for a new paradigm. J Am Coll Cardiol 2011;57:1801–1810.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4942282</ArticleId><ArticleId IdType="pubmed">21527153</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenberg SM, Ziai WC, Cordonnier C, et al. . 2022 Guideline for the management of patients with spontaneous intracerebral hemorrhage: a guideline from the American Heart Association/American Stroke Association. Stroke 2022;53:e282–e361.</Citation><ArticleIdList><ArticleId IdType="pubmed">35579034</ArticleId></ArticleIdList></Reference><Reference><Citation>Higashida R, Alberts MJ, Alexander DN, et al. . Interactions within stroke systems of care: a policy statement from the American Heart Association/American Stroke Association. Stroke 2013;44:2961–2984.</Citation><ArticleIdList><ArticleId IdType="pubmed">23988638</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffman B, Tomes N, Grob R, Schlesinger M. Patients as policy actors: a century of changing markets and missions. Rutgers University Press; 2011.</Citation></Reference><Reference><Citation>Ho A. Live like nobody is watching: Relational autonomy in the age of artificial intelligence health monitoring. Oxford University Press; 2023.</Citation></Reference><Reference><Citation>Li J, Chung S, Luft H. Implementing Smoking Cessation Counseling for Lung Cancer Screening-Eligible Patients. Abstracts from the 24th annual Health Care Systems Research Network Conference, April 11-13, 2018, Minneapolis, Minnesota. J Patient Cent Res Rev. 2018;5(1).</Citation></Reference><Reference><Citation>Islam H, Islam R. Comment on: Evaluation of pulmonary function and exercise capacity after COVID-19 pneumonia. Heart Lung J Cardiopulm Acute Care 2023;59:181.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9894771</ArticleId><ArticleId IdType="pubmed">36781363</ArticleId></ArticleIdList></Reference><Reference><Citation>Islam R, Kundu S, Jha SB, et al. . Cirrhosis and coagulopathy: mechanisms of hemostasis changes in liver failure and their management. Cureus 2022;14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9063731</ArticleId><ArticleId IdType="pubmed">35518552</ArticleId></ArticleIdList></Reference><Reference><Citation>Baranovskii DS, Klabukov ID, Krasilnikova OA, et al. . Prolonged prothrombin time as an early prognostic indicator of severe acute respiratory distress syndrome in patients with COVID-19 related pneumonia. Curr Med Res Opin 2021;37:21–25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7738209</ArticleId><ArticleId IdType="pubmed">33210948</ArticleId></ArticleIdList></Reference><Reference><Citation>Umbrajkar S, Stankowski RV, Rezkalla S, et al. . Cardiovascular health and disease in the context of COVID-19. Cardiol Res 2021;12:67.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7935632</ArticleId><ArticleId IdType="pubmed">33738009</ArticleId></ArticleIdList></Reference><Reference><Citation>Song Y, Chen B, Fang J, et al. . Engineering materials and devices for the prevention, diagnosis, and treatment of COVID-19 and infectious diseases. Nanomaterials 2023;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10490511</ArticleId><ArticleId IdType="pubmed">37686965</ArticleId></ArticleIdList></Reference><Reference><Citation>Soto J, Linsley C, Song Y, et al. . Engineering materials and devices for the prevention, diagnosis, and treatment of COVID-19 and infectious diseases. Nanomaterials 2023;13:2455.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10490511</ArticleId><ArticleId IdType="pubmed">37686965</ArticleId></ArticleIdList></Reference><Reference><Citation>Rando HM, Greene CS, Robson MP, et al. . SARS-CoV-2 and COVID-19: An evolving review of diagnostics and therapeutics. Manubot; 2021.</Citation></Reference><Reference><Citation>Hui DS, Zumla A. Historical perspective: other human coronavirus infectious diseases, SARS and MERS. COVID-19 (ERS Monograph). Sheffield Eur Respir Soc 2021;1:28–38.</Citation></Reference><Reference><Citation>Makris K, Haliassos A, Chondrogianni M, et al. . Blood biomarkers in ischemic stroke: potential role and challenges in clinical practice and research. Crit Rev Clin Lab Sci 2018;55:294–328.</Citation><ArticleIdList><ArticleId IdType="pubmed">29668333</ArticleId></ArticleIdList></Reference><Reference><Citation>Gil-García CA, Cueto-Robledo G, Gonzalez-Hermosillo LM, et al. . Non thrombotic pulmonary embolism associated with non-Hodgkin lymphoma. Curr Probl Cardiol 2023:102001.</Citation><ArticleIdList><ArticleId IdType="pubmed">37506958</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang Z, Ma J, Wang Q, et al. . Combination of circulating miRNA-320a/b and D-dimer improves diagnostic accuracy in deep vein thrombosis patients. Med Sci Monitor Int Med J Exp Clin Res 2018;24:2031.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5903311</ArticleId><ArticleId IdType="pubmed">29622762</ArticleId></ArticleIdList></Reference><Reference><Citation>DeFilippis AP, Chapman AR, Mills NL, et al. . Assessment and treatment of patients with type 2 myocardial infarction and acute nonischemic myocardial injury. Circulation 2019;140:1661–1678.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6855329</ArticleId><ArticleId IdType="pubmed">31416350</ArticleId></ArticleIdList></Reference><Reference><Citation>Obeagu EI, Babar Q. Covid-19 and sickle cell anemia: susceptibility and severity. J Clin Lab Res 2021;3:2768–0487.</Citation></Reference><Reference><Citation>Nnodim J, Njoku-Obi T, Ohalete C, et al. . Perspective of Covid 19 hesistancy. Madonna Univ J Med Health Sci 2022;2:235–238.</Citation></Reference><Reference><Citation>Obeagu EI, Babar Q, Vincent CC, et al. . Infants immunization: challenges of other vaccines due to Covid-19 pandemic. J Bioinnov 2021;10:1056–1066.</Citation></Reference><Reference><Citation>Obeagu EI, Scott GY, Amekpor F, et al. . A systematic review on the role of untreated inflammation of the genital tract in SARS COV 2 transmission. Madonna Univ J Med Health Sci 2023;3:19–24.</Citation></Reference><Reference><Citation>Obeagu EI, Hamisi S, Bunu UO. An update on cytokine storm in covid-19 infection: pivotal to the survival of the patients. Int J Adv Res Biol Sci 2023;10:171–180.</Citation></Reference><Reference><Citation>Obeagu EI. Mental health care during the COVID-19 pandemic. J Public Health Nutr 2020;3:12–32.</Citation></Reference><Reference><Citation>Asogwa EI, Obeagu EI, Abonyi OS, et al. . Mitigating the psychological impacts of COVID-19 in Southern Nigeria; public awareness of routine exercises and preventive measures. J Pharm Res Int 2021;33(30A):72–83.</Citation></Reference><Reference><Citation>Obeagu EI, Babar Q, Vincent CC, et al. . Pulmonary embolism in Covid-19 pandemic: a threat to recovery of the infected patients. J Pharm Res Int 2021;33(42A):90–98.</Citation></Reference><Reference><Citation>Obeagu EI, Babar Q, Uduchi IO, et al. . An update on transfusion related immunomodulation (TRIM) in a time of COVID-19 pandemic. J Pharm Res Int 2021;33(42A):135–146.</Citation></Reference><Reference><Citation>Okorie N, Adeniran OC, Adimabua OP, et al. . Pathological changes among Norvegicus Rattus exposed on novel smoked Bambusa Vulgaris (Bamboo) Leaf: cigarette substitute during COVID-19 lockdown in Nigeria. J Adv Med Pharm Sci 2022;24:30–39.</Citation></Reference><Reference><Citation>Etido A, Obeagu EI, Okafor CJ, et al. . The dynamics of innate and adaptive immune response to SARS Cov-2 infection and its limitations in human beings. J Pharm Res Int 2021;33(45A):10–25.</Citation></Reference><Reference><Citation>Obeagu EI, Obeagu GU, Chukwueze CM, et al. . Inappropriate use of personal protective equipment among health workers: a review of associated factors. Int J Curr Res Chem Pharm Sci 2023;10:27–34.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>